343 related articles for article (PubMed ID: 31534548)
1. Co-delivery of glycyrrhizin and doxorubicin by alginate nanogel particles attenuates the activation of macrophage and enhances the therapeutic efficacy for hepatocellular carcinoma.
Wang QS; Gao LN; Zhu XN; Zhang Y; Zhang CN; Xu D; Cui YL
Theranostics; 2019; 9(21):6239-6255. PubMed ID: 31534548
[TBL] [Abstract][Full Text] [Related]
2. Functional alginate nanoparticles for efficient intracellular release of doxorubicin and hepatoma carcinoma cell targeting therapy.
Guo H; Lai Q; Wang W; Wu Y; Zhang C; Liu Y; Yuan Z
Int J Pharm; 2013 Jul; 451(1-2):1-11. PubMed ID: 23618965
[TBL] [Abstract][Full Text] [Related]
3. Janus nanocarrier-based co-delivery of doxorubicin and berberine weakens chemotherapy-exacerbated hepatocellular carcinoma recurrence.
Zhang F; Jia Y; Zheng X; Shao D; Zhao Y; Wang Z; Dawulieti J; Liu W; Sun M; Sun W; Pan Y; Cui L; Wang Y; He K; Zhang M; Li J; Dong WF; Chen L
Acta Biomater; 2019 Dec; 100():352-364. PubMed ID: 31563690
[TBL] [Abstract][Full Text] [Related]
4. Glycyrrhetinic acid-conjugated polymeric prodrug micelles co-delivered with doxorubicin as combination therapy treatment for liver cancer.
Yang T; Lan Y; Cao M; Ma X; Cao A; Sun Y; Yang J; Li L; Liu Y
Colloids Surf B Biointerfaces; 2019 Mar; 175():106-115. PubMed ID: 30529816
[TBL] [Abstract][Full Text] [Related]
5. Lactosylated liposomes for targeted delivery of doxorubicin to hepatocellular carcinoma.
Zhou X; Zhang M; Yung B; Li H; Zhou C; Lee LJ; Lee RJ
Int J Nanomedicine; 2012; 7():5465-74. PubMed ID: 23093902
[TBL] [Abstract][Full Text] [Related]
6. Glycyrrhizin Conjugated Dendrimer and Multi-Walled Carbon Nanotubes for Liver Specific Delivery of Doxorubicin.
Chopdey PK; Tekade RK; Mehra NK; Mody N; Jain NK
J Nanosci Nanotechnol; 2015 Feb; 15(2):1088-100. PubMed ID: 26353617
[TBL] [Abstract][Full Text] [Related]
7. Codelivery of doxorubicin and elacridar to target both liver cancer cells and stem cells by polylactide-co-glycolide/d-alpha-tocopherol polyethylene glycol 1000 succinate nanoparticles.
Chen D; Pan X; Xie F; Lu Y; Zou H; Yin C; Zhang Y; Gao J
Int J Nanomedicine; 2018; 13():6855-6870. PubMed ID: 30498347
[TBL] [Abstract][Full Text] [Related]
8. In vivo pharmacokinetics, biodistribution and the anti-tumor effect of cyclic RGD-modified doxorubicin-loaded polymers in tumor-bearing mice.
Wang C; Li Y; Chen B; Zou M
Colloids Surf B Biointerfaces; 2016 Oct; 146():31-8. PubMed ID: 27244048
[TBL] [Abstract][Full Text] [Related]
9. Preparation of a Self-Assembled Rhein-Doxorubicin Nanogel Targeting Mitochondria and Investigation on Its Antihepatoma Activity.
Wu L; Shi Y; Ni Z; Yu T; Chen Z
Mol Pharm; 2022 Jan; 19(1):35-50. PubMed ID: 34890210
[TBL] [Abstract][Full Text] [Related]
10. Galactosylated gelatin nanovectors of doxorubicin inhibit cell proliferation and induce apoptosis in hepatocarcinoma cells.
Garg M; Madan J; Pandey RS; Sardana S; Katyal A; Chandra R
Anticancer Drugs; 2012 Sep; 23(8):836-45. PubMed ID: 22407250
[TBL] [Abstract][Full Text] [Related]
11. Multilayer micro-dispersing system as oral carriers for co-delivery of doxorubicin hydrochloride and P-gp inhibitor.
Feng C; Li J; Mu Y; Kong M; Li Y; Raja MA; Cheng XJ; Liu Y; Chen XG
Int J Biol Macromol; 2017 Jan; 94(Pt A):170-180. PubMed ID: 27720963
[TBL] [Abstract][Full Text] [Related]
12. Intratumoral Administration of Thermosensitive Hydrogel Co-Loaded with Norcantharidin Nanoparticles and Doxorubicin for the Treatment of Hepatocellular Carcinoma.
Gao B; Luo J; Liu Y; Su S; Fu S; Yang X; Li B
Int J Nanomedicine; 2021; 16():4073-4085. PubMed ID: 34163160
[TBL] [Abstract][Full Text] [Related]
13. A54 Peptide Modified and Redox-Responsive Glucolipid Conjugate Micelles for Intracellular Delivery of Doxorubicin in Hepatocarcinoma Therapy.
Liu N; Tan Y; Hu Y; Meng T; Wen L; Liu J; Cheng B; Yuan H; Huang X; Hu F
ACS Appl Mater Interfaces; 2016 Dec; 8(48):33148-33156. PubMed ID: 27934140
[TBL] [Abstract][Full Text] [Related]
14. Preparation of a dual cored hepatoma-specific star glycopolymer nanogel via arm-first ATRP approach.
Lou S; Zhang X; Zhang M; Ji S; Wang W; Zhang J; Li C; Kong D
Int J Nanomedicine; 2017; 12():3653-3664. PubMed ID: 28553105
[TBL] [Abstract][Full Text] [Related]
15. Targeted hepatocellular carcinoma therapy: transferrin modified, self-assembled polymeric nanomedicine for co-delivery of cisplatin and doxorubicin.
Zhang X; Li J; Yan M
Drug Dev Ind Pharm; 2016 Oct; 42(10):1590-9. PubMed ID: 26942448
[TBL] [Abstract][Full Text] [Related]
16. Effect of co-treatment with doxorubicin and verapamil loaded into chitosan nanoparticles on diethylnitrosamine-induced hepatocellular carcinoma in mice.
Abo Mansour HE; El-Batsh MM; Badawy NS; Mehanna ET; Mesbah NM; Abo-Elmatty DM
Hum Exp Toxicol; 2020 Nov; 39(11):1528-1544. PubMed ID: 32519553
[TBL] [Abstract][Full Text] [Related]
17. Glycyrrhizin-modified O-carboxymethyl chitosan nanoparticles as drug vehicles targeting hepatocellular carcinoma.
Shi L; Tang C; Yin C
Biomaterials; 2012 Oct; 33(30):7594-604. PubMed ID: 22796165
[TBL] [Abstract][Full Text] [Related]
18. Liver cancer cells: targeting and prolonged-release drug carriers consisting of mesoporous silica nanoparticles and alginate microspheres.
Liao YT; Liu CH; Yu J; Wu KC
Int J Nanomedicine; 2014; 9():2767-78. PubMed ID: 24940057
[TBL] [Abstract][Full Text] [Related]
19. Anticancer efficacy of photodynamic therapy with hematoporphyrin-modified, doxorubicin-loaded nanoparticles in liver cancer.
Chang JE; Yoon IS; Sun PL; Yi E; Jheon S; Shim CK
J Photochem Photobiol B; 2014 Nov; 140():49-56. PubMed ID: 25090224
[TBL] [Abstract][Full Text] [Related]
20. Negative-charge-functionalized mesoporous silica nanoparticles as drug vehicles targeting hepatocellular carcinoma.
Xie M; Xu Y; Shen H; Shen S; Ge Y; Xie J
Int J Pharm; 2014 Oct; 474(1-2):223-31. PubMed ID: 25149125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
